Pfizer Looks To Enter Oral Anti-Thrombotic Market Through Schering AG Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company in-licenses Schering AG’s preclinical oral ADP receptor antagonist line; agents are targeted for chronic use in prophylaxis of arterial thrombosis and other CV events. Pfizer has one marketed anti-thrombotic, none in clinical development.
You may also be interested in...
J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration
Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.
J&J Gains Phase III Oral Anti-Thrombotic Agent Under Bayer Collaboration
Bayer emphasizes Johnson & Johnson’s experience in the cardiovascular field as key asset of the deal. NDA submission for the factor Xa inhibitor is anticipated in 2007.
Eisai Licenses U.S. Rights To Fragmin From Pfizer
Agreement to license the dalteparin sodium anti-coagulant is aimed at strengthening Eisai’s position in the U.S. critical care market.